Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Citius Pharmaceuticals, Inc. - Common Stock
(NQ:
CTXR
)
2.910
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
160
Open
2.910
Bid (Size)
2.850 (2)
Ask (Size)
3.160 (1)
Prev. Close
2.910
Today's Range
2.910 - 2.910
52wk Range
2.440 - 26.75
Shares Outstanding
145,979,429
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Why Nutanix Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket
November 27, 2024
Via
Benzinga
US Stocks Mixed; Best Buy Posts Downbeat Earnings
November 26, 2024
Via
Benzinga
Performance
YTD
-85.61%
-85.61%
1 Month
-12.81%
-12.81%
3 Month
-78.87%
-78.87%
6 Month
-81.74%
-81.74%
1 Year
-85.25%
-85.25%
More News
Read More
CTXR Stock Earnings: Citius Pharma Meets EPS for Q3 2024
August 12, 2024
Via
InvestorPlace
Penny Stock Citius Pharmaceuticals Secures Its First FDA Approval For Skin Cancer Drug A Year After FDA Rejection
August 08, 2024
Via
Benzinga
Exposures
Product Safety
Citius Pharmaceuticals To Receive 65 Million Shares Of TenX Keane For Merger Of Citius Oncology
August 06, 2024
Via
News Direct
This Pharma Company Is Preparing To Launch Its Lead Candidate
July 25, 2024
Via
News Direct
Citius Pharmaceuticals Nears Market Breakthrough With Two Leading Products
July 30, 2024
Via
News Direct
Biotech Stocks Race Towards Solutions for Cutaneous T-Cell Lymphoma (CTCL)
July 18, 2024
Via
Newsfile
Exposures
Product Safety
Analysts Hunt for Undervalued Biotech Stocks
July 17, 2024
Via
Newsfile
Topics
Economy
Initial Public Offering
Exposures
Interest Rates
Securities Market
Citius Pharmaceuticals (CTXR) Eyes Breakthrough with Late-Stage Drug Pipeline Poised for Regulatory Approval
July 17, 2024
Via
AB Newswire
Bloodstream Infections - From Threats to Solutions
July 11, 2024
Via
Newsfile
Topics
Death
Exposures
Death
Citius Pharmaceuticals (CTXR) Nears Key FDA Decisions and Launch Plans for 2024
July 11, 2024
Via
AB Newswire
Exposures
Product Safety
Biopharma Stocks Transformative Innovation for the Future of Health
July 11, 2024
Via
Newsfile
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Citius Pharma's 'Antibiotic Lock' Effective In Patients With Catheter-Associated Bloodstream Infections
May 21, 2024
Via
Benzinga
Yogi Tea Recalls: Yogi Brand Recalls 900,000 Tea Bags for Pesticide Residue
May 21, 2024
Via
InvestorPlace
Topics
Product Recall
Exposures
Legal
Product Safety
VFS Stock Alert: VinFast Plunges on NHTSA Probe
May 21, 2024
Via
InvestorPlace
Why Is Citius Pharmaceuticals (CTXR) Stock Up 11% Today?
May 21, 2024
Via
InvestorPlace
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
May 21, 2024
Via
Benzinga
Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) Featured in Coverage of the EF Hutton Annual Global Conference
May 16, 2024
Via
Investor Brand Network
Exposures
Product Safety
CTXR Stock Earnings: Citius Pharma Meets EPS for Q2 2024
May 14, 2024
Via
InvestorPlace
Citius Pharmaceuticals (NASDAQ: CTXR) Advances Oncology Asset, Paving Way For Spin Out Of Advanced T-cell Lymphoma Treatment
April 18, 2024
Via
News Direct
Topics
Death
Exposures
Death
12 Health Care Stocks Moving In Thursday's Pre-Market Session
April 18, 2024
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
April 18, 2024
Via
InvestorPlace
Sidoti Events, LLC’s Virtual November Micro-Cap Conference
November 14, 2023
Via
ACCESSWIRE
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
October 24, 2023
Via
Benzinga
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.